Tempest Therapeutics Inc expected to post a loss of $2.60 a share - Earnings Preview

Tempest Therapeutics Inc TPST is expected to show no change in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Tempest Therapeutics Inc is for a loss of $2.60 per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Tempest Therapeutics Inc is $9.00, about 16.8% above its last closing price of $7.49